Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic

Remi A. Kessler, Maureen A. Mealy, Michael Levy

Research output: Contribution to journalReview articlepeer-review

73 Scopus citations


Neuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune disease of the central nervous system that primarily attacks the optic nerves and spinal cord leading to blindness and paralysis. The spectrum of the disease has expanded based on the specificity of the autoimmune response to the aquaporin-4 water channel on astrocytes. With wider recognition of NMOSD, a standard of care for treatment of this condition has condition based on a growing series of retrospective and prospective studies. This review covers the present state of the field in the treatment of acute relapses, preventive approaches, and therapies for symptoms of NMOSD.

Original languageEnglish (US)
Article number2
Pages (from-to)1-15
Number of pages15
JournalCurrent Treatment Options in Neurology
Issue number1
StatePublished - Jan 1 2016


  • Azathioprine
  • Eculizumab
  • Immunosuppression
  • Mycophenolate
  • Neuromyelitis optica spectrum disorder
  • Rituximab

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic'. Together they form a unique fingerprint.

Cite this